Stockreport

Is Suvretta's Stake Cut and FDA's Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF US$35.78 million while still keeping the company as its largest reported holding, as Arcutis reported strong ZORYVE adoption and FDA acceptance of a supplemental NDA for [Read more]